NKGen Biotech is currently conducting clinical trials to evaluate the potential benefits of our SNK therapy with the goal of improving outcomes for cancer patients.
NKGen Biotech is working to bring innovative cellular immune therapies to people with cancer. We are currently conducting clinical trials with our super-activated NK cell therapy (SNK01) in cancer patients. Clinical trials ensure that a new therapy is safe and effective by administering the treatment to trial patients and healthy volunteers to generate safety and efficacy data. Clinical trials are a key component in the cell therapy regulatory approval process and are an essential step in the path towards commercialization. Learn more about clinical trials at www.clinicaltrials.gov.
Active Clinical Trials
|SNK01-US01||Advanced Solid Tumors, Adult||Sarcoma Oncology Research Center, Santa Monica, CA||Enrolling Patients||NCT03941262||Phase I, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Patients with Pathologically Confirmed Cancer Refractory to Conventional Therapy|
For more information, please click on the NCT# above to access the study details. You will be taken to the www.clinicaltrials.gov study specific webpage. Information on enrollment can be found by contacting the study coordinator listed in the ‘Contacts and Locations’ section. When considering enrolling in a clinical trial, please consult with your healthcare provider first to discuss the risks and the benefits and to determine whether participating in a clinical trial is right for you.